← Eichor
Condition: Mrd Positive Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mrd Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Le
Phase 2 · 15 location(s) · Goethe University · NCT06648889Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Phase 2 · 1 location(s) · Sheng-Li Xue, MD · NCT05940961Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06718244Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06144606MRD-positive AML Clinical Study
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07131059RGL-305+ Lymphoma + Exploratory Clinical Study
NA · 1 location(s) · Fudan University · NCT07006012Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07407920Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Phase 2 · 1 location(s) · Baylor Research Institute · NCT06517212Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
Phase 4 · 1 location(s) · Fudan University · NCT06561620Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06213636FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07645469Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Maligna
Phase N/A · 14 location(s) · Tempus AI · NCT07211178Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06885476A Study of Chidamide With AZA in MRD Positive AML After Transplant
NA · 1 location(s) · Guangdong Provincial People's Hospital · NCT06066905Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
Phase N/A · 1 location(s) · National Cancer Center, Japan · NCT05433753To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07280494The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
EARLY_Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07126782Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06985485Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
Phase 1 · 1 location(s) · Mendus · NCT07651878A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Phase 2 · 41 location(s) · MedSIR · NCT05708235Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients
Phase N/A · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06479460Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adul
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06608732MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07463651
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.